210 related articles for article (PubMed ID: 30422039)
1. Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?
Olson SR; Koprowski S; Hum J; McCarty OJT; DeLoughery TG; Shatzel JJ
Platelets; 2019; 30(6):796-798. PubMed ID: 30422039
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
3. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
[TBL] [Abstract][Full Text] [Related]
4. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
Xu H; Cai R
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
[No Abstract] [Full Text] [Related]
5. Thrombocytopenia in Chronic Liver Disease: New Management Strategies.
Nilles KM; Flamm SL
Clin Liver Dis; 2020 Aug; 24(3):437-451. PubMed ID: 32620282
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
Orme ME; Bentley R; Marcella S; Peck-Radosavljevic M; Perard R; Wedemeyer H; Yoshiji H; Agarwal K; Dusheiko G
Adv Ther; 2022 Sep; 39(9):4169-4188. PubMed ID: 35836089
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
Khemichian S; Terrault NA
Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
[TBL] [Abstract][Full Text] [Related]
8. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
[TBL] [Abstract][Full Text] [Related]
9. Avatrombopag: A Review in Thrombocytopenia.
Markham A
Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
[TBL] [Abstract][Full Text] [Related]
10. The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function.
Takeuchi H; Furuichi Y; Yoshimasu Y; Kasai Y; Abe M; Sugimoto K; Itoi T
J Nippon Med Sch; 2021 Jan; 87(6):325-333. PubMed ID: 32238734
[TBL] [Abstract][Full Text] [Related]
11. Management of Thrombocytopenia in Patients with Chronic Liver Disease.
Saab S; Brown RS
Dig Dis Sci; 2019 Oct; 64(10):2757-2768. PubMed ID: 31011942
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
Gilreath J; Lo M; Bubalo J
Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
[TBL] [Abstract][Full Text] [Related]
13. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
Kuter DJ
Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
[TBL] [Abstract][Full Text] [Related]
14. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
Peck-Radosavljevic M; Simon K; Iacobellis A; Hassanein T; Kayali Z; Tran A; Makara M; Ben Ari Z; Braun M; Mitrut P; Yang SS; Akdogan M; Pirisi M; Duggal A; Ochiai T; Motomiya T; Kano T; Nagata T; Afdhal N
Hepatology; 2019 Oct; 70(4):1336-1348. PubMed ID: 30762895
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
Katsube T; Shimizu R; Fukuhara T; Kano T; Wajima T
Clin Pharmacokinet; 2019 Nov; 58(11):1469-1482. PubMed ID: 31055790
[TBL] [Abstract][Full Text] [Related]
16. Thrombocytopenia in Chronic Liver Disease and the Role of Thrombopoietin Agonists.
Miller JB; Figueroa EJ; Haug RM; Shah NL
Gastroenterol Hepatol (N Y); 2019 Jun; 15(6):326-332. PubMed ID: 31391802
[TBL] [Abstract][Full Text] [Related]
17. Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease.
Aguilar C
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):231-6. PubMed ID: 23518832
[TBL] [Abstract][Full Text] [Related]
18. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.
Gallo P; Terracciani F; Di Pasquale G; Esposito M; Picardi A; Vespasiani-Gentilucci U
World J Gastroenterol; 2022 Aug; 28(30):4061-4074. PubMed ID: 36157107
[TBL] [Abstract][Full Text] [Related]
19. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
Maan R; de Knegt RJ; Veldt BJ
Drugs; 2015 Nov; 75(17):1981-92. PubMed ID: 26501978
[TBL] [Abstract][Full Text] [Related]
20. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag.
Abdela J
Clin Med Insights Blood Disord; 2019; 12():1179545X19875105. PubMed ID: 31673229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
